Inhalation and Nasal Spray Generic Drugs Market Report 2026

The inhalation and nasal spray generic drugs market size has grown strongly in recent years. It will grow from $31.53 billion in 2025 to $33.96 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increasing prevalence of asthma and COPD, expiration of branded drug patents, rising healthcare cost pressures, growing awareness of respiratory diseases, expansion of generic drug approvals.

The inhalation and nasal spray generic drugs market size is expected to see strong growth in the next few years. It will grow to $45.92 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to aging population with chronic respiratory conditions, increasing air pollution levels, growth in home-based respiratory care, rising penetration in emerging markets, continuous development of advanced inhalation devices. Major trends in the forecast period include rising adoption of generic inhalers and nasal sprays, growing focus on cost-effective respiratory therapies, increasing demand for metered-dose and dry powder inhalers, expansion of combination drug formulations, improved drug delivery device design for patient compliance.

The increasing prevalence of chronic respiratory diseases worldwide is expected to drive the growth of inhalation and nasal spray generic drugs. These conditions affect the airways and other lung structures, with rising cases attributed to factors such as increased exposure to air pollution, smoking, and environmental irritants that impair lung function. Inhalation and nasal spray generic drugs help manage chronic respiratory diseases by providing quick, targeted relief directly to the airways, enhancing symptom control and improving daily breathing. For example, a research study published in December 2023 by JAMA Network Open, a medical journal from the American Medical Association, projected that the global burden of chronic obstructive pulmonary disease (COPD) could lead to nearly 600 million cases by 2050, representing a 23% increase in prevalence. As a result, the growing incidence of chronic respiratory diseases worldwide is expected to contribute to market expansion.

Leading companies in the inhalation and nasal spray generic drugs market are focusing on developing innovative solutions, such as advanced generic nasal spray formulations, to address the growing demand for cost-effective respiratory therapies, wider accessibility, and clinically equivalent alternatives to branded products. These advanced generic nasal sprays are designed to replicate the reference product’s delivery performance, deposition profile, and therapeutic effect, while providing more affordable treatment options compared to traditional branded sprays. For example, in January 2025, Lupin Limited, a global pharmaceutical company based in India, received FDA approval for its ANDA for Ipratropium Bromide Nasal Solution (0.06%), a generic version of Boehringer Ingelheim’s Atrovent Nasal Spray. Manufactured at Lupin’s Pithampur facility, this solution offers anticholinergic action to relieve rhinorrhea in adults and children aged 5 years and older, providing consistent dosing, localized treatment, reduced systemic exposure, and a more affordable option for patients.

In July 2024, Grand Pharmaceutical Group Limited, a China-based manufacturer of active pharmaceutical ingredients, acquired Baiji Pharmaceutical for an undisclosed amount. The acquisition was aimed at enhancing Grand Pharma's respiratory segment by incorporating a technologically advanced nasal spray platform. Baiji Pharmaceutical, also based in China, specializes in nasal spray formulations for allergic rhinitis and other respiratory conditions.

Major companies operating in the inhalation and nasal spray generic drugs market are Teva Pharmaceuticals Inc., Sandoz International GmbH, Akorn Operating Company LLC, Cipla Inc., Apotex Inc., Impax Laboratories LLC, Bausch Health Companies Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Jubilant Biosys Limited, Alembic Pharmaceuticals Limited, Laurus Labs Limited, Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Wockhardt Limited, Alkem Laboratories Limited, Unichem Laboratories Limited, Indoco Remedies Limited, Natco Pharma Limited, Aesica Pharmaceuticals Limited, Labiana Pharmaceuticals S.L.U., Summit Biosciences Inc.

North America was the largest region in the inhalation and nasal spray generic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalation and nasal spray generic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalation and nasal spray generic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the inhalation and nasal spray generic drugs market by increasing costs for imported active pharmaceutical ingredients, device components, and packaging materials used in inhalers and sprays. This has affected price competitiveness and margins, particularly for corticosteroids and bronchodilator segments, with Asia-Pacific and Europe being most impacted due to heavy reliance on cross-border supply chains. However, tariffs are also encouraging local manufacturing, regional API sourcing, and capacity expansion in domestic markets, supporting long-term supply chain resilience and cost optimization.

The inhalation and nasal spray generic drugs market research report is one of a series of new reports that provides inhalation and nasal spray generic drugs market statistics, including inhalation and nasal spray generic drugs industry global market size, regional shares, competitors with a inhalation and nasal spray generic drugs market share, detailed inhalation and nasal spray generic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation and nasal spray generic drugs industry. This inhalation and nasal spray generic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Inhalation and nasal spray generic drugs are commonly used as the primary delivery methods for medications aimed at treating asthma and chronic obstructive pulmonary disease (COPD). Nasal sprays, which are liquid medications applied to the nose, help relieve nasal congestion (stuffy nose). Inhalers, on the other hand, are devices that administer medication in the form of a spray, inhaled through the mouth or nose.

The key drug classes for inhalation and nasal spray generics include corticosteroids, bronchodilators, antihistamines, combination treatments, and decongestant sprays. Corticosteroids, which encompass glucocorticoids and mineralocorticoids, are a group of steroid hormones produced by the adrenal cortex. These drugs are commonly used to alleviate inflammation, severe allergies, skin conditions, asthma, and arthritis. They are prescribed for a variety of conditions, including asthma, COPD, allergic rhinitis, and more. The patient demographic for these drugs includes geriatric, adult, and pediatric patients. The primary end-users are hospitals, home care providers, and other healthcare settings.

The inhalation and nasal spray generic drugs market consists of sales of fluticasone, budesonide, beclomethasone, albuterol, epinephrine, phenylephrine hydrochloride, oxymetazoline and hydrochloride. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.